Autoantibodies in early detection of breast cancer

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


In spite of the progress made in treatment and early diagnosis, breast cancer remains a major public health issue worldwide. Although modern image-based screening modalities have significantly improved early diagnosis, around 15% to 20% of breast cancers still go undetected. In underdeveloped countries, lack of resources and cost concerns prevent implementing mammography for routine screening. Noninvasive, low-cost, blood-based markers for early breast cancer diagnosis would be an invaluable alternative that would complement mammography screening. Tumor-specific autoantibodies are excellent biosensors that could be exploited to monitor disease-specific changes years before disease onset. Although clinically informative autoantibody markers for early breast cancer screening have yet to emerge, progress has been made in the development of tools to discover and validate promising autoantibody signatures. This review focuses on the current progress toward the development of autoantibody-based early screening markers for breast cancer.

Original languageEnglish (US)
Pages (from-to)2475-2485
Number of pages11
JournalCancer Epidemiology Biomarkers and Prevention
Issue number12
StatePublished - Dec 2020

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Autoantibodies in early detection of breast cancer'. Together they form a unique fingerprint.

Cite this